Screener
ArriVent BioPharma, Inc. AVBP Business Segments — Other General And Administrative Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherGeneralAndAdministrativeExpense.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| (in thousands) | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Other Firmonertinib costs | 3,883 | 2,262 |
| Total Firmonertinib | 15,083 | 14,304 |
| Research and development: Early-stage programs | 12,307 | 40,981 |
| Research and development: Personnel-related and other internal costs | 10,227 | 6,005 |
| General and administrative: Personnel-related costs | 6,183 | 3,331 |
| General and administrative: Other costs | 2,311 | 2,151 |
| Other segment items (a) | (2,791) | (2,385) |
| Net loss | $43,320 | $64,387 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s business segments — other general and administrative expense?
- ArriVent BioPharma, Inc. (AVBP) reported business segments — other general and administrative expense of $2.31M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s business segments — other general and administrative expense changed year-over-year?
- ArriVent BioPharma, Inc.'s business segments — other general and administrative expense increased by 7.4% year-over-year, from $2.15M to $2.31M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s business segments — other general and administrative expense?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s business segments — other general and administrative expense has grown at a 38.8% compound annual growth rate (CAGR), from $4.55M to $8.78M.
- What does business segments — other general and administrative expense mean?
- This metric encompasses general corporate operating expenses not directly tied to personnel, such as facility leases, professional services, insurance, and office-related costs. It represents the baseline administrative burden required to sustain business operations outside of direct R&D activities. Managing these costs is critical for preserving cash runway in clinical-stage biopharmaceutical companies.
Ask your AI about ArriVent BioPharma, Inc.'s business segments — other general and administrative expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude